Zynerba gains on fragile X syndrome data

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) jumped $3.25 (53%) to $9.44 on Thursday after reporting that its synthetic cannabidiol (CBD) gel ZYN002 met the primary endpoint in the open-label Phase II FAB-C trial to treat children with fragile X syndrome. The company plans to meet with FDA in 1H18 to discuss a Phase II/III program in the indication that is slated to start next year.

Prior to Thursday's gain, Zynerba had lost over $115 million in market cap since Aug. 7 after the company said ZYN002 missed the primary endpoint in the Phase II STAR 1 trial to treat focal seizures in adult epilepsy patients. Later in August, ZYN002 missed the primary endpoint in the Phase II STOP trial to treat knee pain due to osteoarthritis (see BioCentury Extra, Aug. 7 & Aug. 14)...